- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02322853
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors (OLYMPE)
A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment guidelines include tamoxifen, fulvestrant (an ER antagonist) and exemestane as available options (NCCN treatment guidelines 2012), but in this context of resistance, their efficacy are poor.
Some results confirm the possibility to improve the efficacy of tamoxifen in metastatic setting by a combination with therapy targeting signal transduction pathways. Other transduction pathways seem to be involved in endocrine sensitivity/resistance, such as RAS/RAF/MEK/MAK pathway.
LY2228820 inhibits the activity of p38 MAPK (selective inhibitor of the α and β isoforms of p38 MAPK in vitro) and reduces phosphorylation of its cellular target, MAPK-activated protein kinase 2 (MAPKAP-K2).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Bordeaux, França
- Institut Bergonié
-
Caen, França
- Centre Francois Baclesse
-
Clermont -Ferrand, França
- Centre Jean Perrin
-
Dijon, França
- Centre Georges-François Leclerc
-
Lyon, França
- Centre Leon Berard
-
Marseille, França
- Institut Paoli Calmettes
-
Nantes, França
- Institut de cancerologie de l'ouest
-
Paris, França
- Hegp, Ap-Hp
-
Paris, França
- Hôpital St Louis, AP-HP
-
Rennes, França
- Centre Eugène Marquis
-
Rouen, França
- Centre Henri Becquerel
-
St Cloud, França
- Institut Curie
-
Toulouse, França
- Institut Claudius Regaud
-
Villejuif, França
- Institut Gustave Roussy
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Women with histologically confirmed breast cancer
- 18 < age < 80 years old
Menopausal status Women are considered post-menopausal and not of child bearing potential if they have had
- 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or
- 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or
- surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
- ER-positive status by local laboratory testing (>10% by IHC) and HER2-negative status (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen available.
- Disease progression defined as inoperable locally advanced or metastatic breast cancer (MBC) excluding aggressive visceral disease requiring other approaches, such as chemotherapy
Disease refractory to aromatase inhibitors (AI) defined as:
- recurrence while on, or within 12 months of end of adjuvant treatment with aromatase inhibitor, or
- progression while on, or within 3 months of end of AI for locally advanced or MBC
- Patients who have received fulvestrant are eligible
- Maximum 2 previous lines of chemotherapy for MBC
- Performance Status (PS) ≤ 2
- Patient able to swallow and retain oral medication
Measurable or evaluable lesions as per RECIST 1.1
- Measurable disease (≥ 20 mm by conventional techniques or ≥ 10 mm by spiral computed tomography scan) or
- Non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
- Patients with only pleural effusion and/or ascites are not eligible.
Adequate bone marrow and organ function as defined by the following laboratory values:
- Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
- Platelets (plt) ≥ 100 x 109/L
- Hemoglobin (Hgb) ≥ 9 g/dl
- INR ≤ 1.5 without any anticoagulation treatment
- Serum creatinine ≤ 1.5 x ULN
- Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal range (or < 3.0 x ULN if liver metastases are present)
- Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from CBC count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
Exclusion Criteria:
• Previous treatment with p38 MAPK inhibitors or Tamoxifen in metastatic setting (adjuvant treatment by tamoxifen is allowed)
- More than 2 lines of chemotherapy for locally advanced and/or metastatic breast cancer
- Brain metastasis
- Other malignancy (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer).
- Clinically significant (i.e. active) cardiovascular disease: cerebro-vascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or higher; or serious cardiac arrhythmia requiring medication.
- Have had a major bowel resection that would alter oral drug absorption.
- Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Are receiving concurrent administration of immunosuppressive therapy
- Concurrent participation in any therapeutic clinical trial
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: TAMOXIFEN
Tamoxifen will be administered daily orally Patients will receive study medication until disease progression or unacceptable toxicity |
hormonotherapy
|
Experimental: TAMOXIFEN + LY2228820
Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally Patients will receive study medication until disease progression or unacceptable toxicity |
hormonotherapy
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.
Prazo: at 6 months after treatment start.
|
at 6 months after treatment start.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
- To evaluate the toxicity profile (Safety and Tolerability) of the LY2228820 in combination with tamoxifen
Prazo: From date of randomization until study participation (during average 12 months)
|
Adverse events description and grade in all participants
|
From date of randomization until study participation (during average 12 months)
|
- To estimate the Progression-Free Survival of the LY2228820 in combination with tamoxifen
Prazo: evaluated every 8-12 weeks (during average 12 months)
|
evaluated every 8-12 weeks (during average 12 months)
|
|
- To assess the overall survival of the LY2228820 in combination with tamoxifen
Prazo: From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months
|
From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months
|
|
- To assess response duration of the LY2228820 in combination with tamoxifen
Prazo: evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months)
|
evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Christelle LEVY, MD, c.levy@baclesse.unicancer.fr
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças de pele
- Neoplasias
- Neoplasias por local
- Doenças da mama
- Neoplasias da Mama
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Agentes Antineoplásicos Hormonais
- Antagonistas Hormonais
- Agentes de Conservação da Densidade Óssea
- Antagonistas de Estrogênio
- Moduladores Seletivos de Receptores de Estrogênio
- Moduladores de Receptores de Estrogênio
- Tamoxifeno
Outros números de identificação do estudo
- OLYMPE / 2013-005084-29
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de Mama Metastático
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos